Assembly biosciences doses first participant in phase 1a clinical study of oral entry inhibitor candidate abi-6250 for hepatitis delta virus

– phase 1a study will evaluate single and multiple ascending doses of abi-6250 in healthy participants with data expected in q3 2025 – – biomarker of abi-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – south san francisco, calif., feb. 26, 2025 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the phase 1a trial of abi-6250, the company's orally bioavailable, small molecule hepatitis delta virus (hdv) entry inhibitor candidate.
ASMB Ratings Summary
ASMB Quant Ranking